Stock Track | GENFLEET-B Soars 5.34% Intraday as Key Drug Added to China's National Reimbursement List

Stock Track

03/25

Shares of GENFLEET-B (02595) surged 5.34% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.

The sharp increase appears to be driven by the announcement that Genfleet Therapeutics' KRAS G12C inhibitor, fulzerasib, has been added to China's national drug reimbursement list. This marks the company's first marketed product in mainland China, with coverage scheduled to take effect in 2026, potentially expanding patient access and driving future revenue growth.

Genfleet also reported advancing multiple RAS-targeted programs in its pipeline, including a KRAS G12D candidate, which could support broader partnering opportunities and future commercialization plans for the company.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1136203088"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136203088\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136203088?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136203088","market":"hk","top_or_hot":-1,"title":"Stock Track | GENFLEET-B Soars 5.34% Intraday as Key Drug Added to China's National Reimbursement List","media":"Stock Track","content":"<p>Shares of GENFLEET-B (02595) surged 5.34% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.</p><p>The sharp increase appears to be driven by the announcement that Genfleet Therapeutics' KRAS G12C inhibitor, fulzerasib, has been added to China's national drug reimbursement list. This marks the company's first marketed product in mainland China, with coverage scheduled to take effect in 2026, potentially expanding patient access and driving future revenue growth.</p><p>Genfleet also reported advancing multiple RAS-targeted programs in its pipeline, including a KRAS G12D candidate, which could support broader partnering opportunities and future commercialization plans for the company.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GENFLEET-B Soars 5.34% Intraday as Key Drug Added to China's National Reimbursement List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GENFLEET-B Soars 5.34% Intraday as Key Drug Added to China's National Reimbursement List\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-03-25 10:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of GENFLEET-B (02595) surged 5.34% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.</p><p>The sharp increase appears to be driven by the announcement that Genfleet Therapeutics' KRAS G12C inhibitor, fulzerasib, has been added to China's national drug reimbursement list. This marks the company's first marketed product in mainland China, with coverage scheduled to take effect in 2026, potentially expanding patient access and driving future revenue growth.</p><p>Genfleet also reported advancing multiple RAS-targeted programs in its pipeline, including a KRAS G12D candidate, which could support broader partnering opportunities and future commercialization plans for the company.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"勁方醫藥-B","start_time":0,"source_url":"","article_id":"1136203088","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136203088","pubTimestamp":1774404047,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of GENFLEET-B (02595) surged 5.34% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.The sharp increase appears to be driven by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02595":"劲方医药-B"},"translate_title":"个股追踪|GENFLEET-B盘中大涨5.34%关键药物加入中国国家报销目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":1},"content_text":"Shares of GENFLEET-B (02595) surged 5.34% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.The sharp increase appears to be driven by the announcement that Genfleet Therapeutics' KRAS G12C inhibitor, fulzerasib, has been added to China's national drug reimbursement list. This marks the company's first marketed product in mainland China, with coverage scheduled to take effect in 2026, potentially expanding patient access and driving future revenue growth.Genfleet also reported advancing multiple RAS-targeted programs in its pipeline, including a KRAS G12D candidate, which could support broader partnering opportunities and future commercialization plans for the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}